The Enterprise Value as of November 2024 (TTM) for Kiniksa Pharmaceuticals, Ltd. (KNSA) is 1.51B

According to Kiniksa Pharmaceuticals, Ltd.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.51B. This represents a change of 14.24% compared to the average of 1.32B of the last 4 quarters.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Historical Enterprise Value (quarterly & annually)

How has KNSA Enterprise Value performed in the past?

The mean historical Enterprise Value of Kiniksa Pharmaceuticals, Ltd. over the last ten years is 746.38M. The current 1.51B Enterprise Value has changed 20.17% with respect to the historical average. Over the past ten years (40 quarters), KNSA's Enterprise Value was at its highest in in the September 2024 quarter at 1.71B. The Enterprise Value was at its lowest in in the June 2017 quarter at 0.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Kiniksa Pharmaceuticals, Ltd. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Average Enterprise Value

How has KNSA Enterprise Value performed in the past?

The current Enterprise Value of Kiniksa Pharmaceuticals, Ltd. (KNSA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Kiniksa Pharmaceuticals, Ltd. (KNSA) Enterprise Value vs. Peers

How is KNSA’s Enterprise Value compared to its peers?

Kiniksa Pharmaceuticals, Ltd.’s Enterprise Value is less than Nuvalent, Inc. (6.17B), greater than Ventyx Biosciences, Inc. (121.57M), less than Arcellx, Inc. (4.76B), greater than Cullinan Oncology, Inc. (808.96M), greater than Day One Biopharmaceuticals, Inc. (1.09B), less than Structure Therapeutics Inc. (1.91B), less than Karuna Therapeutics, Inc. (12.43B), greater than Phathom Pharmaceuticals, Inc. (1.50B), greater than Replimune Group, Inc. (752.35M), greater than Nuvectis Pharma, Inc. (103.22M), greater than Lyra Therapeutics, Inc. (21.80M), greater than Kronos Bio, Inc. (14.20M), greater than Gossamer Bio, Inc. (312.50M), greater than Cogent Biosciences, Inc. (1.23B), greater than Larimar Therapeutics, Inc. (455.86M), greater than Kura Oncology, Inc. (1.33B), less than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than Spero Therapeutics, Inc. (9.03M), greater than Bolt Biotherapeutics, Inc. (37.94M), greater than Coherus BioSciences, Inc. (222.94M), less than Gracell Biotechnologies Inc. (5.47B), greater than Neoleukin Therapeutics, Inc. (-6333315.00),

Build a custom stock screener for Kiniksa Pharmaceuticals, Ltd. (KNSA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kiniksa Pharmaceuticals, Ltd. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kiniksa Pharmaceuticals, Ltd. (KNSA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kiniksa Pharmaceuticals, Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.